List of Excipients in Branded Drug ALCAFTADINE

« Back to Dashboard

Generic Drugs Containing ALCAFTADINE

Company	Ingredient	NDC	Excipient
Aurohealth LLC	alcaftadine	58602-605	BENZALKONIUM CHLORIDE
Aurohealth LLC	alcaftadine	58602-605	EDETATE DISODIUM
Aurohealth LLC	alcaftadine	58602-605	HYDROCHLORIC ACID
Aurohealth LLC	alcaftadine	58602-605	SODIUM CHLORIDE
Aurohealth LLC	alcaftadine	58602-605	SODIUM HYDROXIDE
Aurohealth LLC	alcaftadine	58602-605	SODIUM PHOSPHATE, MONOBASIC
Aurohealth LLC	alcaftadine	58602-605	WATER

What are the Most Frequently-Used Excipients in ALCAFTADINE?

# Of NDCs	Excipient
3	BENZALKONIUM CHLORIDE
3	EDETATE DISODIUM
3	HYDROCHLORIC ACID
3	SODIUM CHLORIDE
3	SODIUM HYDROXIDE
3	SODIUM PHOSPHATE, MONOBASIC
3	WATER

Alcaftadine Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Alcaftadine is a once-daily ophthalmic antihistamine and mast-cell stabilizer marketed in the United States as Lastacaft 0.25%. Its commercial opportunity has shifted from active-ingredient differentiation to formulation, preservative-free delivery, packaging, OTC positioning, and generic manufacturing efficiency. The strongest excipient strategy is a preservative-free, low-irritation ophthalmic solution supported by a multidose container or unit-dose format.

What is alcaftadine and how is it marketed?

Alcaftadine is an H1 histamine receptor antagonist with activity against mast cells and eosinophil-related allergic responses. It is administered as one drop in each affected eye once daily for the prevention of itching associated with allergic conjunctivitis. The product is an aqueous ophthalmic solution containing 0.25% alcaftadine, equivalent to 2.5 mg/mL. [1]

Item	Commercial profile
Active ingredient	Alcaftadine
Dosage form	Ophthalmic solution
Strength	0.25%
Route	Topical ocular
Dosing	One drop per affected eye once daily
U.S. brand	Lastacaft
Original sponsor	Allergan
Current commercial owner	Bausch + Lomb
Regulatory status	FDA-approved; U.S. OTC commercialization
Therapeutic category	Ocular allergy, antihistamine and mast-cell stabilizer
Biosimilar relevance	None; alcaftadine is a small molecule

The original prescription product used a preserved aqueous formulation. The current OTC product has been positioned around preservative-free use, which targets consumers with frequent exposure to eye drops and patients sensitive to benzalkonium chloride.

What excipients are used in alcaftadine ophthalmic formulations?

The original Lastacaft formulation used a conventional ophthalmic excipient system consisting of a preservative, tonicity agents, buffering agents, a chelating agent, purified water, and pH adjusters. The preservative-free formulation uses a different commercial strategy.

Preserved formulation

The prescription formulation identified benzalkonium chloride at 0.01% as the antimicrobial preservative. Other listed inactive ingredients included dibasic sodium phosphate, sodium chloride, edetate disodium, hydrochloric acid and sodium hydroxide for pH adjustment, and purified water. [1]

This system is technically familiar and inexpensive. Its disadvantages are commercial:

• Benzalkonium chloride can create concern for ocular-surface irritation.
• Chronic or frequent exposure can affect the tear film and corneal epithelium.
• Preservative sensitivity can limit use in dry-eye and contact-lens populations.
• Preserved products have weaker differentiation in a crowded OTC allergy market.

Preservative-free formulation

The current OTC formulation is marketed as preservative-free and uses excipients including glycerin, phosphate buffer components, sodium chloride, edetate disodium, purified water, and pH-adjusting agents, according to product labeling. [2]

The commercial value of the preservative-free system is greater than the cost of the excipients themselves. It supports:

1. Positioning for sensitive eyes.
2. Use by consumers who prefer preservative-free products.
3. Differentiation from lower-cost preserved generic products.
4. Potential inclusion in dry-eye and ocular-surface treatment regimens.
5. Premium pricing through OTC branding and packaging.

How should an alcaftadine excipient system be designed?

The excipient strategy should prioritize ocular tolerability, chemical stability, microbial control, container compatibility, and drop-size consistency.

Buffer selection

Phosphate buffering is conventional for ophthalmic products, but it has potential limitations. In patients with compromised corneal surfaces, phosphate-containing formulations can raise compatibility concerns, particularly where calcium deposition risk is relevant. A citrate or borate buffer could create a differentiated alternative, subject to compatibility, safety, and regulatory review.

The target pH should balance:

• Alcaftadine chemical stability.
• Ocular comfort.
• Solubility and physical stability.
• Preservative performance where applicable.
• Compatibility with the primary container.

A formulation should avoid unnecessarily high buffer capacity. High buffer capacity can increase stinging because the formulation resists rapid adjustment to tear-fluid pH.

Tonicity adjustment

Sodium chloride is the simplest tonicity agent. Glycerin can contribute both tonicity and lubrication. A glycerin-containing system may provide a more consumer-friendly profile than a formulation relying entirely on sodium chloride, particularly for patients who report burning or dryness after instillation.

The practical target is near-isotonicity without making the drop excessively viscous. Hypertonic or hypotonic formulations can produce discomfort, reflex tearing, and reduced ocular residence.

Chelation

Edetate disodium supports preservative performance by binding divalent metal ions and can reduce metal-catalyzed degradation pathways. It may also improve antimicrobial robustness in a preserved formulation.

In a preservative-free product, edetate disodium can remain useful as a stability excipient, but its inclusion should be supported by a demonstrated role in chemical stability or container-closure performance. Reducing unnecessary excipients can simplify labeling and support a cleaner consumer proposition.

Viscosity modification

A modest viscosity increase could extend ocular residence and reduce drainage through the nasolacrimal duct. Candidate excipients include hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, povidone, and hyaluronic-acid derivatives.

The trade-off is material:

• Higher viscosity may increase residence time.
• It can also blur vision temporarily.
• It may complicate drop formation.
• It can alter bottle emptying and dose uniformity.
• It may create a less acceptable sensory profile for OTC users.

A low-viscosity system with consistent drop geometry is likely more commercially attractive than a visibly gelled formulation.

What formulation patents could protect an alcaftadine product?

A new alcaftadine product would likely obtain limited protection from the original compound patent estate. Commercially meaningful protection would instead come from formulation, container, manufacturing, and use claims.

Potential patentable subject matter

Patent category	Potential claim focus	Commercial value
Preservative-free formulation	Alcaftadine with selected buffer, tonicity agent, chelator, and pH range	Moderate
Low-irritation formulation	Defined osmolarity, pH, buffer capacity, or excipient ratios	Moderate
Multidose delivery	Preservative-free bottle with microbial-barrier valve	High
Unit-dose packaging	Sterile single-use ampoules or blow-fill-seal units	Moderate
Stability	Defined impurity limits and storage conditions	Moderate
Drop-size control	Container geometry and actuator design	Moderate
Combination therapy	Alcaftadine with lubricants or other ocular actives	Potentially high
Manufacturing process	Sterile filtration, aseptic filling, or crystallization controls	Low to moderate
Method of use	Treatment of allergic conjunctivitis or specific patient populations	Usually limited

A formulation patent should not rely only on a list of conventional excipients. Stronger claims would connect the excipient combination to measurable performance, such as improved stability, reduced ocular irritation, lower extractables, improved multidose sterility, or a defined drop-size range.

Patent-strength assessment

The likely strength of a new formulation estate would vary by claim type:

• Broad claims covering alcaftadine with sodium chloride, phosphate buffer, and purified water would face substantial obviousness risk.
• Narrow claims directed to a specific preservative-free system with demonstrated stability and tolerability would be stronger.
• Device claims covering a multidose preservative-free container may provide the most durable commercial barrier.
• Method-of-use claims may be difficult to enforce against generic ophthalmic solutions because the same product can be dispensed for the same indication under different labeling.
• Process claims are valuable only if the process is difficult to design around or if product impurities reveal its use.

The commercial target should be a layered estate rather than a single formulation patent.

When does alcaftadine lose exclusivity?

Alcaftadine has no biosimilar exclusivity issue because it is a chemically synthesized small molecule. Competition is governed by ordinary generic-drug rules, formulation patents, listed patents, regulatory exclusivity, trademarks, and product-device differentiation.

The original compound and formulation patent positions are separate from the current OTC brand strategy. Earlier alcaftadine patents have reached or approached the end of their ordinary patent terms, making generic and private-label competition more relevant than compound-level exclusivity. Current Orange Book listings and FDA regulatory submissions determine whether any listed patent remains capable of delaying an ANDA approval. [3]

Exclusivity issue	Relevance to alcaftadine
New chemical entity exclusivity	Historical, not the current commercial barrier
Pediatric exclusivity	No material current barrier identified in the cited product materials
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orange Book patents	Relevant to ANDA certification and potential litigation
Formulation patents	Potentially relevant for preservative-free or device-specific products
Trademark	Important for Lastacaft brand protection
OTC regulatory status	Supports direct consumer commercialization

What is the Orange Book and Paragraph IV risk for alcaftadine?

An ANDA applicant seeking to market alcaftadine ophthalmic solution must address listed patents associated with the reference product. A Paragraph IV certification may trigger patent litigation if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

The practical risk is greatest where a listed patent covers:

• The 0.25% ophthalmic solution.
• A preservative-free formulation.
• A specific pH or buffer system.
• A container-closure system.
• A method of treating ocular allergy.

A generic applicant can reduce litigation exposure by using a different excipient system, a different container, or a non-infringing label. This creates a strategic split in the market:

1. Preserved generic alcaftadine can compete on price.
2. Preservative-free generic alcaftadine can compete directly with the current OTC brand.
3. Device-enabled products can maintain differentiation after compound patents expire.

The absence of a biological product means there is no interchangeable-biosimilar pathway, no reference-product biologic exclusivity period, and no immunogenicity-based switching issue.

What FDA regulatory pathway applies to alcaftadine products?

A conventional generic alcaftadine ophthalmic solution would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy FDA’s product-specific requirements for an ophthalmic solution.

A reformulated or reformulated OTC product may require an NDA or supplemental NDA, depending on the proposed change and regulatory basis. The FDA approved the switch of Lastacaft from prescription to OTC use, allowing consumer-directed commercialization for allergic-eye itching. [4]

The major regulatory burden for a preservative-free ophthalmic product is not the excipient list alone. It is the full control strategy:

• Sterility assurance.
• Container-closure integrity.
• Extractables and leachables.
• Particulate control.
• Drop-size and delivered-dose uniformity.
• In-use stability.
• Microbial ingress resistance for multidose packaging.
• Chemical stability and degradation products.

What commercial opportunities exist for alcaftadine excipients?

Preservative-free multidose delivery

This is the highest-value opportunity. A multidose bottle that maintains sterility without benzalkonium chloride can provide the convenience of a standard bottle while supporting a premium formulation claim.

The key technology is the container, not merely the excipient composition. Opportunities include:

• One-way valves.
• Sterile airless systems.
• Hydrophobic microbial barriers.
• Low-dead-volume actuators.
• Metered-dose pumps.
• Tamper-evident preservative-free bottles.

Unit-dose products

Unit-dose ampoules can provide a strong sterility profile and clear preservative-free positioning. They are suitable for:

• Pediatric use.
• Travel.
• Contact-lens users.
• Institutional dispensing.
• Samples and promotional distribution.

Their disadvantages are higher packaging cost, more waste, and reduced consumer convenience.

Lubricating alcaftadine combinations

A combination of alcaftadine with a lubricant could address patients with allergic conjunctivitis and concurrent ocular-surface discomfort. Candidate lubricating excipients include glycerin, povidone, carboxymethylcellulose, and hyaluronic-acid derivatives.

The regulatory and patent opportunity would be stronger if the combination demonstrated a clinically relevant benefit, such as reduced stinging, longer comfort, or improved adherence, rather than merely adding a known lubricant.

Phosphate-free formulations

A citrate-, borate-, or alternative-buffer formulation could target consumers and clinicians who prefer to avoid phosphate-containing ophthalmic products. The formulation would require strong stability and tolerability data because a buffer substitution may affect alcaftadine solubility, degradation, and ocular comfort.

Global and regional products

Excipient strategy can be tailored by market:

Market	Commercial opportunity
United States	OTC preservative-free brand and generic competition
Europe	Preservative-free products for ocular-surface sensitivity
Japan	Small-volume, high-compliance ophthalmic packaging
Emerging markets	Preserved low-cost generic solutions
Hospitals and clinics	Unit-dose sterile products
Specialty eye care	Device-enabled multidose systems

How does alcaftadine compare with competing allergy eye drops?

Alcaftadine competes with ketotifen, olopatadine, azelastine, and cromolyn-based products. The relevant differentiation is once-daily dosing, antihistamine activity, mast-cell stabilization, preservative profile, price, and OTC recognition.

Product category	Typical differentiation	Excipient opportunity
Alcaftadine	Once-daily allergy relief; preservative-free brand positioning	Multidose PF, lubricant combination
Ketotifen	Established OTC generic competition	Low-cost preserved or PF generic
Olopatadine	Strong brand and generic presence	Premium PF and combination systems
Azelastine	Antihistamine-focused positioning	Comfort and taste-drip reduction
Cromolyn	Mast-cell stabilization	Less direct competition in modern OTC use

Alcaftadine’s commercial weakness is the availability of chemically similar OTC alternatives. Its formulation opportunity is therefore more defensible than a simple active-ingredient claim.

Which companies are challenging alcaftadine’s market?

Competition comes from three groups:

1. Branded OTC ophthalmic companies selling Lastacaft.
2. Generic manufacturers filing or commercializing alcaftadine ophthalmic solution.
3. Companies selling competing antihistamine and mast-cell stabilizer products.

The most credible competitive threats are generic alcaftadine products with lower acquisition cost and established OTC allergy brands with larger distribution. Device suppliers can also capture value by licensing preservative-free multidose systems to multiple ophthalmic manufacturers.

Public company disclosures do not generally report standalone alcaftadine revenue. Revenue exposure is therefore best assessed through product status, channel placement, pricing, market share, and dependence on preservative-free claims rather than through separately reported brand sales.

What manufacturing and intellectual-property barriers exist?

The active ingredient is not the primary barrier. The important barriers are:

• Sterile ophthalmic manufacturing capacity.
• Validated aseptic filling.
• Low-extractables packaging.
• Preservative-free multidose container technology.
• Consistent drop-size performance.
• Stability under real-world storage conditions.
• Regulatory documentation for OTC labeling.
• Freedom to operate around device patents.

A contract development and manufacturing organization with ophthalmic filling, container testing, and sterile device capability can reduce development time. An excipient supplier with a proprietary low-irritation or solubilizing system could pursue licensing with generic manufacturers, brand owners, or device companies.

What generic launch scenarios exist for alcaftadine?

Scenario 1: Preserved low-cost generic

This is the easiest product to develop and is likely to compete primarily on price. It has limited brand differentiation and may be less attractive to ocular-surface-sensitive consumers.

Scenario 2: Preservative-free generic

This product would compete more directly with the current OTC brand. Its success would depend on packaging cost, consumer recognition, FDA labeling, and freedom to operate around any formulation or device patents.

Scenario 3: Premium device-enabled product

A metered-dose or airless system could support a higher price and reduce microbial contamination risk. The device may create a stronger commercial moat than the active ingredient.

Scenario 4: Alcaftadine-lubricant combination

A combination product could target allergic conjunctivitis patients with dryness or irritation. It would require clinical and regulatory substantiation but could create a distinct product position.

Key Takeaways

• Alcaftadine is a small-molecule ophthalmic antihistamine marketed as Lastacaft 0.25%.
• The highest-value excipient opportunity is a preservative-free formulation supported by a multidose microbial-barrier container.
• Benzalkonium chloride is commercially useful for low-cost preserved products but weakens premium ocular-surface positioning.
• Glycerin, sodium chloride, phosphate buffers, edetate disodium, and pH adjusters form the core excipient platform in current labeling.
• New broad excipient claims are likely vulnerable; stronger protection would combine formulation limits with stability, tolerability, drop-size, or container performance.
• Biosimilar risk is irrelevant. Generic ANDA competition is the principal post-exclusivity threat.
• Formulation-device patents may be more valuable than additional active-ingredient patents.
• The strongest commercial opportunities are preservative-free multidose products, unit-dose packaging, lubricant combinations, and phosphate-free systems.
• Alcaftadine revenue is not generally disclosed as a separate line item by public companies, so commercial exposure should be evaluated through product and channel metrics.

FAQs

Is alcaftadine compatible with preservative-free ophthalmic development?

Yes. A preservative-free alcaftadine product can use a sterile single-dose package or a multidose container with microbial-barrier technology. The principal development challenges are sterility, in-use stability, and container performance.

Which excipient is most commercially important in alcaftadine eye drops?

The container-closure system is more commercially important than any single excipient. Glycerin, sodium chloride, buffer salts, and edetate disodium are replaceable, while a validated preservative-free multidose device can support meaningful product differentiation.

Can a company patent an alcaftadine and lubricant combination?

Potentially. Patentability would depend on claim scope and demonstrated technical or clinical advantages. A combination containing only known ingredients without unexpected performance would face a higher obviousness risk.

Does alcaftadine have biosimilar competition?

No. Alcaftadine is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than biosimilar approval procedures.

What is the most attractive alcaftadine licensing opportunity?

A proprietary preservative-free multidose delivery system is the strongest licensing target. It can be supplied to brand owners and generic manufacturers and may create value across multiple ophthalmic active ingredients.

References

1. U.S. Food and Drug Administration. (2010). Lastacaft (alcaftadine ophthalmic solution) prescribing information. FDA.

2. DailyMed. (n.d.). Lastacaft: Alcaftadine ophthalmic solution, 0.25% labeling. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (2021). FDA approves first over-the-counter eye drop for itching associated with allergic conjunctivitis. FDA.